There are more than 1.2 million people in the UK on warfarin, but fewer than two per cent of them benefit from self-monitoring, despite evidence that it can cut the risk of death by nearly forty percent and more than halve the risk of strokes. ACSMA is launching a new campaign with the specific objective of achieving greater access via prescription to International Normalised Ratio (INR) self-monitoring technology for patients receiving warfarin therapy. ACSMA comprises four of the UK’s leading charities and patient groups – AntiCoagulation Europe; the Children’s Heart Federation; the Atrial Fibrillation Association; the Mechanical Heart Valve Support Group.